Trial Details
Not RecruitingBasic Information
| Clinical ID | c5393 |
|---|---|
| Identifier | CTRI/2018/07/014719 |
| Trial Title | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to.Evaluate the Testicular Safety of Filgotinib in Adult Males with.Moderately to Severely Active Inflammatory Bowel Disease. |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NULL |
|---|---|
| Conditions | Health Condition 1: K509- Crohns disease, unspecified.Health Condition 2: null- Moderately to Severely Active Ulcerative Colitis. |
| Interventions | Intervention1: Filgotinib 200mg oral tablet: Filgotinib 200mg oral tablet once daily 26 weeksControl Intervention1: Placebo to match Filgotinib 200mg oral tablet: Placebo to match Filgotinib 200mg oral tablet once daily 26 weeks |
Participant Information
| Sponsor | Gilead Sciences Inc |
|---|---|
| City | NULL |
| Country/Region | Australia;Austria;Belgium;Canada;Germany;Hungary;Iceland;India;Ireland;Italy;Netherlands;New Zealand;Norway;Poland;Portugal;Russia;Sri Lanka;Sweden;Switzerland;Ukraine;United Kingdom;United States |
Enrollment Criteria
| Sex Requirement | NOT SPECIFIED |
|---|---|
| Age Requirement | NULL |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | NULL |
|---|---|
| Primary Completion Date | NULL |
| Completion Date | NULL |